Diagnostic Biomarkers of Dilated Cardiomyopathy
Overview
Affiliations
Background: Dilated cardiomyopathy (DCM) is a condition involving dilation of cardiac chambers, which results in contraction impairment. Besides invasive and non-invasive diagnostic procedures, cardiac biomarkers are of great importance in both diagnosis and prognosis of the disease. These biomarkers are categorized into three groups based on their site; cardiomyocyte biomarkers, microenvironmental biomarkers and macroenvironmental biomarkers.
Aims: In this review, an overview of characteristics, epidemiology, etiology and clinical manifestations of DCM is provided. In addition, the most important biomarkers, of all three categories, and their diagnostic and prognostic values are discussed.
Conclusion: Considering the association of DCM with conditions such as infections and autoimmunity, which are prevalent among the population, introducing efficient diagnostic tools is of high value for the early detection of DCM to prevent its severe complications. The three discussed classes of biomarkers are potential candidates for the detection of DCM. However, further studies are necessary in this regard.
Li X, Aizezi A, Li Y, Li Y, Liu F, Zhao Q Heliyon. 2025; 11(3):e41927.
PMID: 39991223 PMC: 11847283. DOI: 10.1016/j.heliyon.2025.e41927.
Diverse Concepts in Definitions of Dilated Cardiomyopathy: Theory and Practice.
Myers M, Breznen B, Zhong Y, Maruyama S, Bueno C, Bastien A Cardiol Res. 2024; 15(5):319-329.
PMID: 39420975 PMC: 11483116. DOI: 10.14740/cr1679.
Li N, Wang J, Wang X, Zha L Int J Med Sci. 2024; 21(9):1769-1782.
PMID: 39006834 PMC: 11241094. DOI: 10.7150/ijms.92537.
Huang Y, Li T, Gao S, Li S, Zhu X, Li Y Front Pharmacol. 2023; 14:1290253.
PMID: 38026943 PMC: 10662320. DOI: 10.3389/fphar.2023.1290253.
OPA1, a molecular regulator of dilated cardiomyopathy.
Chen J, Shao J, Wang Y, Wu K, Huang M J Cell Mol Med. 2023; 27(20):3017-3025.
PMID: 37603376 PMC: 10568666. DOI: 10.1111/jcmm.17918.